InvestorsHub Logo
Followers 12
Posts 1387
Boards Moderated 0
Alias Born 06/05/2014

Re: Number sleven post# 270855

Saturday, 05/02/2020 10:20:39 AM

Saturday, May 02, 2020 10:20:39 AM

Post# of 426778
I say we have clarity on US market. As it stands right now, go with assumption we have "XX" number of months of being the only provider of Vascepa until generics are up and running. Then we blow out our own "generic Vascepa". AMRN should be able as a "worst case scenario" put a NPV on that scenario for BP interest. Put a CVR value on if we win appeal. Put a NPV on EU and ROW. Then begin/continue the negotiations. If they are not in negotiations with a BP right now, then we are in trouble. GIA in EU is just idle chatter due to inability to disclose that negotiations are occurring. Just starting to entertain the idea that JT would be gone unless some type of negotiations were occurring. If BOD really wanted GIA, then why keep current CEO after patent ruling. I mean we have heard nothing from BOD after all this. His "wholistic" approach is occurring, sell it all. All just my opinion.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News